Since the beginning of 2014, MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, screening programs and radiology practice has signed several oncology clinical studies led by major pharma sponsors and biotechnology companies. Those studies involve today more than 20 clinical sites in China and more than 50 sites in the ASIA area. For the purpose of these clinical trials, centralized image monitoring managed by MEDIAN has been implemented, with the aim to collect, store, analyze and mine imaging data.
Today, MEDIAN Technologies’ will is to strengthen its presence in China ; the company leverages its experience acquired from pharma projects to support provincial and municipal health authorities to set-up and monitor CT Lung Cancer Screening programs based on centralized image monitoring. In China, MEDIAN Technologies is looking to partner with provincial and municipal health authorities in charge of fighting growing lung cancer mortality, especially due to a high level of PM2.5 pollution and smoking habits (targets : former and current heavy smokers).